ClinicalTrials.gg
CompletedNCT06715670Updated Dec 4, 2025

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

A Phase 1 interventional study of Zibotentan in Liver Cirrhosis, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Liver Cirrhosis by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Liver Cirrhosis · AstraZeneca.

Enrollment
8th of 11
30 · median 40
Started
2024
with 2 others
Phase 1
5 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Liver Cirrhosis by AstraZeneca, this one is the 8th largest by enrollment, is one of 3 that started in 2024, is one of 5 in phase 1, and was the 5th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

1 of the 11 studies in Liver Cirrhosis by AstraZeneca is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Liver Cirrhosis by AstraZeneca, or all of them as a file.
02

Study summary

This study aim to assess the Pharmacokinetics of Zibotentan in Healthy Non-Asian and Japanese Participants.

Read the detailed description

This study will be Phase I, randomized, open-label, single-dose, 4-period, 4-treatment, cross-over study, performed at a single study center.

The study will comprise: Screening Period of maximum 28 days; Four Treatment Periods, separated by 3 washout periods; Final Follow-up Visit within 5 to 7 days after the last study intervention administration. The washout periods will last at least 3 days, resulting in a total dosing-free time of at least 6 full days between each of the 4 treatments. Participant will receive the first dose is on Day 1, then the next dose will be on Day 8 at the earliest.

Each participant will receive 4 different single doses (Dose 1, 2, 3 and 4) of zibotentan, at all 4 studied dose levels in one of the following treatment sequences: ABCD, BDAC, CADB, DCBA.

Each participant will be involved in the study for approximately 9 weeks, depending upon the duration of the washout periods.

03

Conditions studied

  • Liver Cirrhosis

Keywords

  • Chronic kidney disease
  • Treatment sequence
  • Pharmacokinetics
  • Washout periods
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures.
  • Healthy male and female (non-) with suitable veins for cannulation or repeated venipuncture.
  • All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
  • Females of non-childbearing potential must be confirmed at the Screening Visit.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the methods.
  • (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive at Screening.
  • Japanese participant must have Japanese parents and grandparents, were born in Japan, and not have lived outside Japan for over 10 years.
  • Participant is considered non-Asian if their parents and all grandparents are ethnically non-Asian.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which may either put the participant at risk because of participation in the study or influence the results or the participant's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis, laboratory values and vital signs at the Screening Visit.
  • Any positive result on Screening for serum (Hepatitis B surface antigen), HBcAb (Hepatitis B core antibody) or (Human immunodeficiency virus).
  • Clinically significant abnormal findings in vital signs after 10 minutes of supine rest.
  • Clinically important abnormalities in rhythm, conduction, or morphology of the resting electrocardiography () and prolonged > 450 ms, family history of long QT syndrome, or early cardiac death.
  • Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  • Positive screen for drugs of abuse or alcohol at Screening or first admission.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  • Excessive intake of caffeine-containing drinks or food.
  • Use of any prescribed or nonprescribed medication, including antacids, analgesics, herbal remedies, mega dose vitamins, and minerals within 2 weeks before the first administration of the study intervention.
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months before the Screening Visit.
  • Receipt of another new chemical entity within 30 days or 5 half-lives (whichever is longest) of the first administration of the study intervention.
  • Previous receipt of zibotentan within 28 days before Day 1 dosing in the Clinical Unit.
  • Treatment with strong or moderate Cytochrome P450 3A4 () inhibitors or inducers within 28 days or 5 half-lives (whichever is longest) or weak CYP3A4 inhibitors or inducers within 3 days or 3 half-lives (whichever is longest) before dosing.
  • Involvement in the planning and/or conduct of the study.
  • Ongoing or recent minor medical complaints that may interfere with the interpretation of study data or compliance with study procedures.
  • Being vegan or having medical dietary restrictions.
  • Inability to communicate reliably with the Principal Investigator or designee.
  • Being a vulnerable participant, such as those kept in detention, under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment sequence ABCD: Zibotentan

    Participants will receive single dose of Zibotentan in 4 occassions with first Treatment A, followed by Treatment B, Treatment C and then Treatment D with each dose separated by 3 washout periods.

    Drug: Zibotentan

  • Experimental
    Treatment sequence BDAC: Zibotentan

    Participants will receive single dose of Zibotentan in 4 occassions with first Treatment B, followed by Treatment D, Treatment A and then Treatment C with each dose separated by 3 washout periods

    Drug: Zibotentan

  • Experimental
    Treatment sequence CADB: Zibotentan

    Participants will receive single dose of Zibotentan in 4 occassions with first Treatment C, followed by Treatment A, Treatment D and then Treatment B with each dose separated by 3 washout periods.

    Drug: Zibotentan

  • Experimental
    Treatment sequence DCBA: Zibotentan

    Participants will receive single dose of Zibotentan in 4 occassions with first Treatment D, followed by Treatment C, Treatment B and then Treatment A with each dose separated by 3 washout periods.

    Drug: Zibotentan

Interventions

  • Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.

06

What researchers measure

Primary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)

    To characterize the single-dose plasma PK of orally administered zibotentan in healthy non-Asian and Japanese participants.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the single-dose plasma PK of orally administered zibotentan in healthy non-Asian and Japanese participants.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  3. Maximum observed drug concentration (Cmax)

    To characterize the single-dose plasma PK of orally administered zibotentan in healthy non-Asian and Japanese participants

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

Secondary outcomes

  1. Number of participants with adverse events (AEs) receiving single dose

    To assess the safety and tolerability of receiving single dose of orally administered zibotentan.

    Time frame: From Screening (28 days) to follow-up Visit 5 to 7 days post-final dose (approximately 9 weeks)

  2. Concentration at 24 hours post dose (C24)

    To further characterize zibotentan PK in plasma.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  3. Partial area under the concentration time curve from time 0 to 24 hours post-dose (AUC(0-24))

    To further characterize zibotentan PK in plasma.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  4. Time to reach maximum observed concentration (tmax)

    To further characterize zibotentan PK in plasma.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  5. Terminal elimination half-life (t1/2 λz)

    To further characterize zibotentan PK in plasma.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  6. Mean residence time (MRTinf)

    To further characterize zibotentan PK in plasma.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  7. Terminal rate constant (λz)

    To further characterize zibotentan PK in plasma.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  8. Apparent total body clearance (CL/F)

    To further characterize zibotentan PK in plasma.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  9. Apparent volume of distribution based on the terminal phase (Vz/F)

    To further characterize zibotentan PK in plasma.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  10. Individual and cumulative amount of unchanged drug excreted into urine (Ae) (by time point and cumulative)

    To further characterize zibotentan PK in urine.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  11. Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 (fe) (by time point and cumulative)

    To further characterize zibotentan PK in urine.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

  12. Renal clearance (CLR)

    To further characterize zibotentan PK in urine.

    Time frame: Day 1 through Day 3 of each Treatment Period (each Treatment Period is 7 days)

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Feb 2025, 2 months.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 4, 2024
StartActual
Dec 5, 2024
Primary completionActual
Feb 28, 2025
CompletionActual
Feb 28, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06715670
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Dec 5, 2024
Primary completion
Feb 28, 2025
Completion
Feb 28, 2025
Last update
Dec 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZD4054

Start the discussion